Non-alcoholic fatty liver disease (NAFLD) is a growing health concern in the global medical community. With rising prevalence, understanding its pathophysiology and the need for proactive management is critical for healthcare professionals.
NAFLD, characterized by excess fat accumulation in the liver unrelated to alcohol consumption, is now the most common chronic liver disease worldwide. It affects approximately 25% of the global population, with higher prevalence in individuals with type 2 diabetes and obesity.
The pathogenesis of NAFLD is complex and multifactorial, typically described by the 'two-hit' hypothesis. The 'first hit' involves the accumulation of lipids in the liver, leading to steatosis. The 'second hit' is characterized by inflammation, oxidative stress, and fibrogenesis, leading to the progression of NAFLD to non-alcoholic steatohepatitis (NASH), fibrosis, and potentially cirrhosis and hepatocellular carcinoma.
Proactive management of NAFLD involves early detection, lifestyle modifications, and pharmacological interventions. Screening high-risk populations, such as those with obesity and type 2 diabetes, is crucial for early detection. Lifestyle modifications, including weight loss, healthy diet, and regular exercise, are the first-line treatment. Pharmacological interventions are typically reserved for patients with NASH and significant fibrosis. Emerging therapies targeting various aspects of NAFLD pathogenesis are under investigation.
NAFLD is a significant global health concern with complex pathophysiology. Proactive management, including early detection and lifestyle modifications, is essential to prevent disease progression. Further research is needed to develop effective pharmacological therapies. Healthcare professionals play a vital role in the management of this disease, necessitating a comprehensive understanding of NAFLD.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation